Basic and clinical studies on azithromycin in respiratory infections

H. Fukuhara, H. Taba, J. Inadome, M. Tateyama, A. Saito, I. Nakasone, S. Taira, Nobuchika Kusano, S. Hokama, C. Hokama

Research output: Contribution to journalArticle

Abstract

We performed a basic evaluation of azithromycin (AZM), a newly developed oral macrolide antibiotic, and clinically studied its application in the treatment of respiratory infections, with the following results. 1. Antibacterial activity. The minimum growth inhibitory concentrations (MICs) of AZM against 284 strains of 14 species isolated from clinical material were measured and compared with those of erythromycin (EM), roxithromycin (RXM) and clarithromycin (CAM), oral macrolides. Based on the MIC90, AZM showed similar activity to those of EM and CAM against Gram-positive bacteria, and showed the strongest activity in these macrolides against Gram-negative bacteria. 2. Clinical efficacy. AZM was given to 4 patients with pneumonia, 1 patient with chronic bronchitis and 1 patient with acute bronchitis, orally at 250 or 500 mg once a day for 3 days. The clinical response was excellent in 2 cases and good in 4. No adverse reactions or abnormal laboratory findings were observed.

Original languageEnglish
Pages (from-to)278-283
Number of pages6
JournalJapanese Journal of Chemotherapy
Volume43
Issue numberSUPPL. 6
Publication statusPublished - 1995
Externally publishedYes

Fingerprint

Azithromycin
Respiratory Tract Infections
Macrolides
Clarithromycin
Erythromycin
Roxithromycin
Bronchitis
Chronic Bronchitis
Gram-Positive Bacteria
Microbial Sensitivity Tests
Gram-Negative Bacteria
Pneumonia
Anti-Bacterial Agents
Clinical Studies
Growth
Therapeutics

Keywords

  • azithromycin

ASJC Scopus subject areas

  • Pharmacology

Cite this

Fukuhara, H., Taba, H., Inadome, J., Tateyama, M., Saito, A., Nakasone, I., ... Hokama, C. (1995). Basic and clinical studies on azithromycin in respiratory infections. Japanese Journal of Chemotherapy, 43(SUPPL. 6), 278-283.

Basic and clinical studies on azithromycin in respiratory infections. / Fukuhara, H.; Taba, H.; Inadome, J.; Tateyama, M.; Saito, A.; Nakasone, I.; Taira, S.; Kusano, Nobuchika; Hokama, S.; Hokama, C.

In: Japanese Journal of Chemotherapy, Vol. 43, No. SUPPL. 6, 1995, p. 278-283.

Research output: Contribution to journalArticle

Fukuhara, H, Taba, H, Inadome, J, Tateyama, M, Saito, A, Nakasone, I, Taira, S, Kusano, N, Hokama, S & Hokama, C 1995, 'Basic and clinical studies on azithromycin in respiratory infections', Japanese Journal of Chemotherapy, vol. 43, no. SUPPL. 6, pp. 278-283.
Fukuhara H, Taba H, Inadome J, Tateyama M, Saito A, Nakasone I et al. Basic and clinical studies on azithromycin in respiratory infections. Japanese Journal of Chemotherapy. 1995;43(SUPPL. 6):278-283.
Fukuhara, H. ; Taba, H. ; Inadome, J. ; Tateyama, M. ; Saito, A. ; Nakasone, I. ; Taira, S. ; Kusano, Nobuchika ; Hokama, S. ; Hokama, C. / Basic and clinical studies on azithromycin in respiratory infections. In: Japanese Journal of Chemotherapy. 1995 ; Vol. 43, No. SUPPL. 6. pp. 278-283.
@article{c46d48b72bda4d70a42f45e1385107d0,
title = "Basic and clinical studies on azithromycin in respiratory infections",
abstract = "We performed a basic evaluation of azithromycin (AZM), a newly developed oral macrolide antibiotic, and clinically studied its application in the treatment of respiratory infections, with the following results. 1. Antibacterial activity. The minimum growth inhibitory concentrations (MICs) of AZM against 284 strains of 14 species isolated from clinical material were measured and compared with those of erythromycin (EM), roxithromycin (RXM) and clarithromycin (CAM), oral macrolides. Based on the MIC90, AZM showed similar activity to those of EM and CAM against Gram-positive bacteria, and showed the strongest activity in these macrolides against Gram-negative bacteria. 2. Clinical efficacy. AZM was given to 4 patients with pneumonia, 1 patient with chronic bronchitis and 1 patient with acute bronchitis, orally at 250 or 500 mg once a day for 3 days. The clinical response was excellent in 2 cases and good in 4. No adverse reactions or abnormal laboratory findings were observed.",
keywords = "azithromycin",
author = "H. Fukuhara and H. Taba and J. Inadome and M. Tateyama and A. Saito and I. Nakasone and S. Taira and Nobuchika Kusano and S. Hokama and C. Hokama",
year = "1995",
language = "English",
volume = "43",
pages = "278--283",
journal = "Japanese Journal of Chemotherapy",
issn = "1340-7007",
publisher = "Japan Society of Chemotherapy",
number = "SUPPL. 6",

}

TY - JOUR

T1 - Basic and clinical studies on azithromycin in respiratory infections

AU - Fukuhara, H.

AU - Taba, H.

AU - Inadome, J.

AU - Tateyama, M.

AU - Saito, A.

AU - Nakasone, I.

AU - Taira, S.

AU - Kusano, Nobuchika

AU - Hokama, S.

AU - Hokama, C.

PY - 1995

Y1 - 1995

N2 - We performed a basic evaluation of azithromycin (AZM), a newly developed oral macrolide antibiotic, and clinically studied its application in the treatment of respiratory infections, with the following results. 1. Antibacterial activity. The minimum growth inhibitory concentrations (MICs) of AZM against 284 strains of 14 species isolated from clinical material were measured and compared with those of erythromycin (EM), roxithromycin (RXM) and clarithromycin (CAM), oral macrolides. Based on the MIC90, AZM showed similar activity to those of EM and CAM against Gram-positive bacteria, and showed the strongest activity in these macrolides against Gram-negative bacteria. 2. Clinical efficacy. AZM was given to 4 patients with pneumonia, 1 patient with chronic bronchitis and 1 patient with acute bronchitis, orally at 250 or 500 mg once a day for 3 days. The clinical response was excellent in 2 cases and good in 4. No adverse reactions or abnormal laboratory findings were observed.

AB - We performed a basic evaluation of azithromycin (AZM), a newly developed oral macrolide antibiotic, and clinically studied its application in the treatment of respiratory infections, with the following results. 1. Antibacterial activity. The minimum growth inhibitory concentrations (MICs) of AZM against 284 strains of 14 species isolated from clinical material were measured and compared with those of erythromycin (EM), roxithromycin (RXM) and clarithromycin (CAM), oral macrolides. Based on the MIC90, AZM showed similar activity to those of EM and CAM against Gram-positive bacteria, and showed the strongest activity in these macrolides against Gram-negative bacteria. 2. Clinical efficacy. AZM was given to 4 patients with pneumonia, 1 patient with chronic bronchitis and 1 patient with acute bronchitis, orally at 250 or 500 mg once a day for 3 days. The clinical response was excellent in 2 cases and good in 4. No adverse reactions or abnormal laboratory findings were observed.

KW - azithromycin

UR - http://www.scopus.com/inward/record.url?scp=0029623072&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029623072&partnerID=8YFLogxK

M3 - Article

VL - 43

SP - 278

EP - 283

JO - Japanese Journal of Chemotherapy

JF - Japanese Journal of Chemotherapy

SN - 1340-7007

IS - SUPPL. 6

ER -